Brief: Akebia Gets FDA Acceptance Of Resubmission To NDA Of Vadadustat

Akebia Therapeutics

25/10/2023 14:08

Oct 25 (Reuters) - Akebia Therapeutics Inc  AKBA.O :
    * AKEBIA RECEIVES FDA ACCEPTANCE OF RESUBMISSION TO NDA OF
VADADUSTAT FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY
DISEASE
    * AKEBIA THERAPEUTICS INC - MARCH 27, 2024 SET AS USER FEE
GOAL
DATE
    * AKEBIA THERAPEUTICS INC - EXPECT TO HAVE VADADUSTAT
AVAILABLE
SHORTLY FOLLOWING AN APPROVAL
    * AKEBIA THERAPEUTICS INC -  PREPARING FOR A COMMERCIAL
LAUNCH OF
VADADUSTAT IN SECOND HALF OF 2024

Source text for Eikon:  ID:nPn4CxVNxa 
Further company coverage:  AKBA.O 

 ((Reuters.Briefs@thomsonreuters.com))